Literature DB >> 17388700

Preventing recurrent depression: long-term treatment for major depressive disorder.

Pierre Blier1, Martin B Keller, Mark H Pollack, Michael E Thase, John M Zajecka, David L Dunner.   

Abstract

In contrast to continuation therapy, a treatment aimed at suppressing symptoms during a current depressive episode, maintenance therapy is designed to prevent the development of a new episode. Candidates for maintenance therapy include patients who have achieved remission and have had 2 or more lifetime episodes, especially if they have comorbid disorders, ongoing psychosocial stressors, poor symptom control, or severe depressive episodes. Maintenance pharmacotherapy data strongly support the use of antidepressants at the dosage that helped the patient achieve remission. Other maintenance treatment interventions include psychotherapy, especially cognitive-behavioral therapy, and in some extreme cases, electroconvulsive therapy. Maintenance therapy considerations for clinicians include assessing treatment guidelines, addressing nonadherent patients, and measuring medication treatment response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388700

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

Review 1.  From synapse to nucleus: novel targets for treating depression.

Authors:  Herbert E Covington; Vincent Vialou; Eric J Nestler
Journal:  Neuropharmacology       Date:  2009-12-17       Impact factor: 5.250

Review 2.  Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.

Authors:  Charlene Faye; Josephine C Mcgowan; Christine A Denny; Denis J David
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

3.  Cost-effectiveness of In-Home Cognitive Behavioral Therapy for low-income depressed mothers participating in early childhood prevention programs.

Authors:  Robert T Ammerman; Peter J Mallow; John A Rizzo; Frank W Putnam; Judith B Van Ginkel
Journal:  J Affect Disord       Date:  2016-11-03       Impact factor: 4.839

4.  Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders.

Authors:  David J Kolko; Oliver Lindhiem; Jonathan Hart; Oscar G Bukstein
Journal:  J Abnorm Child Psychol       Date:  2014

5.  Gender and age differences in the recurrence of sickness absence due to common mental disorders: a longitudinal study.

Authors:  Petra C Koopmans; Corné Am Roelen; Ute Bültmann; Rob Hoedeman; Jac Jl van der Klink; Johan W Groothoff
Journal:  BMC Public Health       Date:  2010-07-20       Impact factor: 3.295

Review 6.  Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

Authors:  Sidney H Kennedy; Sakina J Rizvi
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

7.  Recurrence of sickness absence due to common mental disorders.

Authors:  Petra C Koopmans; Ute Bültmann; Corné A M Roelen; Rob Hoedeman; Jac J L van der Klink; Johan W Groothoff
Journal:  Int Arch Occup Environ Health       Date:  2010-05-07       Impact factor: 3.015

8.  Brief report: Characteristics of antidepressant use in patients with heart failure.

Authors:  Paul J Mills; Joel E Dimsdale; Suzi Hong; Geoffrey Van Den Brande; Laura Redwine; Barry H Greenberg; Thomas Rutledge
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Long-term fluoxetine treatment induces input-specific LTP and LTD impairment and structural plasticity in the CA1 hippocampal subfield.

Authors:  Francisco J Rubio; Estíbaliz Ampuero; Rodrigo Sandoval; Jorge Toledo; Floria Pancetti; Ursula Wyneken
Journal:  Front Cell Neurosci       Date:  2013-05-09       Impact factor: 5.505

10.  Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD).

Authors:  Baiba Hedegaard Hansen; Jamal Abed Hanash; Alice Rasmussen; Jørgen Fischer Hansen; Morten Birket-Smith
Journal:  Trials       Date:  2009-04-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.